Atara Biotherapeutics, Inc. (ATRA)
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $1.19 per share versus the Zacks Consensus Estimate of a loss of $3.82. This compares to loss of $14 per share a year ago.
Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet
The consensus price target hints at a 33% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.'s ATRA active Investigational New Drug (IND) applications.
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.
US FDA declines to approve Atara Biotherapeutics' cancer therapy
The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' cancer therapy, chemically called tabelecleucel.
Here's Why You Should Consider Buying Atara Biotherapeutics Stock
Here, we discuss some reasons why buying ATRA stock now may turn out to be a prudent move.
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $2.93 per share versus the Zacks Consensus Estimate of a loss of $3.77. This compares to loss of $16.50 per share a year ago.
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
